Total Payments
$195,977
2024 Payments
$6,599
Companies
10
Transactions
85
Payment Breakdown by Category
Research$188,129 (96.0%)
Travel$6,348 (3.2%)
Food & Beverage$1,500 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $188,129 | 46 | 96.0% |
| Travel and Lodging | $6,348 | 18 | 3.2% |
| Food and Beverage | $1,500 | 21 | 0.8% |
Payments by Type
Research
$188,129
46 transactions
General
$7,848
39 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valneva Austria GmbH | $182,271 | 18 | $0 (2022) |
| SANOFI PASTEUR INC. | $4,859 | 26 | $0 (2024) |
| Merck Sharp & Dohme LLC | $2,292 | 14 | $0 (2024) |
| AstraZeneca UK Limited | $2,006 | 3 | $0 (2022) |
| AMAG Pharmaceuticals, Inc. | $1,552 | 7 | $0 (2017) |
| Eli Lilly and Company | $1,366 | 5 | $0 (2024) |
| ModernaTX, Inc. | $1,240 | 8 | $0 (2024) |
| PFIZER INC. | $350.97 | 2 | $0 (2018) |
| AbbVie Inc. | $23.01 | 1 | $0 (2023) |
| Janssen Research & Development, LLC | $16.90 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,599 | 38 | SANOFI PASTEUR INC. ($3,493) |
| 2023 | $2,717 | 15 | SANOFI PASTEUR INC. ($1,366) |
| 2022 | $184,741 | 22 | Valneva Austria GmbH ($182,271) |
| 2020 | $16.90 | 1 | Janssen Research & Development, LLC ($16.90) |
| 2018 | $350.97 | 2 | PFIZER INC. ($350.97) |
| 2017 | $1,552 | 7 | AMAG Pharmaceuticals, Inc. ($1,552) |
All Payment Transactions
85 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/26/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $78.00 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/26/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $49.60 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/26/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $40.00 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/26/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $40.00 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $609.99 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $475.26 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $234.75 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $152.41 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/25/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $80.00 | Research |
| Study: A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | ||||||
| 10/03/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $700.25 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $54.99 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $233.43 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $149.99 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $117.51 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $117.51 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $428.45 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $265.53 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $240.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $120.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $81.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $45.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE ANTIBODY PERSISTENCE AND LONG TERM SAFETY OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | Valneva Austria GmbH | $98,474 | 10 |
| A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | Valneva Austria GmbH | $67,983 | 4 |
| A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | Valneva Austria GmbH | $15,815 | 4 |
| A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | SANOFI PASTEUR INC. | $1,760 | 9 |
| A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | SANOFI PASTEUR INC. | $1,733 | 10 |
| A Phase I/IIa, randomized, observer-blind, placebo-controlled multi-arm study to evaluate the safety and immunogenicity of an RSV/hMPV mRNA vaccine candidate in adult participants aged 60 years and older | SANOFI PASTEUR INC. | $1,366 | 7 |
| A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | Eli Lilly and Company | $535.01 | 1 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $464.00 | 1 |
About Dr. Mark Adams, M.D
Dr. Mark Adams, M.D is a Internal Medicine healthcare provider based in London, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689601387.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Adams, M.D has received a total of $195,977 in payments from pharmaceutical and medical device companies, with $6,599 received in 2024. These payments were reported across 85 transactions from 10 companies. The most common payment nature is "" ($188,129).
Ad
Practice Information
- Specialty Internal Medicine
- Location London, KY
- Active Since 06/27/2006
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1689601387
Products in Payments
- INTRAROSA (Drug) $1,552
- VRAYLAR (Drug) $23.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in London
Nancy Morris, M.d, M.D
Internal Medicine — Payments: $20,207
Internal Medicine $20,207
Dr. Michel Bidros, M.d, M.D
Internal Medicine — Payments: $8,854
Internal Medicine $8,854
Bryon Cook, M.d, M.D
Internal Medicine — Payments: $4,396
Internal Medicine $4,396
Kamran Mahmood, Md, MD
Internal Medicine — Payments: $3,304
Internal Medicine $3,304
Syed Mustafa, Md, Mbbs, MD, MBBS
Internal Medicine — Payments: $2,734
Internal Medicine $2,734
Dr. Emily White, M.d, M.D
Internal Medicine — Payments: $1,579
Internal Medicine $1,579